Carrier-based strategies for targeting protein and peptide drugs to the lungs
Journal Title: The AAPS Journal - Year 2005, Vol 7, Issue 1
Abstract
With greater interest in delivery of protein and peptide-based drugs to the lungs for topical and systemic activity, a range of new devices and formulations are being investigated. While a great deal of recent research has focused on the development of novel devices, attention must now be paid to the formulation of these macromolecular drugs. The emphasis in this review will be on targeting of protein/peptide drugs by inhalation using carriers and ligands.
Authors and Affiliations
Sally-Ann Cryan
Keywords
Related Articles
- EP ID EP681837
- DOI 10.1208/aapsj070104
- Views 80
- Downloads 0
Resistance to the Translation Initiation Inhibitor Silvestrol is Mediated by ABCB1/P-Glycoprotein Overexpression in Acute Lymphoblastic Leukemia Cells
Protein synthesis is a powerful therapeutic target in leukemias and other cancers, but few pharmacologically viable agents are available that affect this process directly. The plant-derived agent silvestrol specifically...
Targeted Delivery of Curcumin to Tumors via PEG-Derivatized FTS-Based Micellar System
The online version of this article (doi:10.1208/s12248-014-9595-6) contains supplementary material, which is available to authorized users.
Recent Advances in Application of Pharmacogenomics for Biotherapeutics
Biotherapeutics (BTs), one of the fastest growing classes of drug molecules, offer several advantages over the traditional small molecule pharmaceuticals because of their relatively high specificity, low off-target effec...
“Fit-for-Purpose” Method Validation and Application of a Biomarker (C-terminal Telopeptides of Type 1 Collagen) in Denosumab Clinical Studies
Biomarkers are used to study drug effects, exposure–response relationships, and facilitate early decision making during development. Denosumab, a fully human monoclonal antibody against receptor activator of nucl...
Intranasal Delivery of Proteins and Peptides in the Treatment of Neurodegenerative Diseases
The blood–brain barrier (BBB) is a major impediment to the therapeutic delivery of peptides and proteins to the brain. Intranasal delivery often provides a non-invasive means to bypass the BBB. Advantages of usin...